Clearside Biomedical, Inc. (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced the completion of the final participant visit in the Company’s ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration (wet AMD). With this milestone complete, the study database is being cleaned and verified. Then the database will be locked and the unblinded data will be analyzed, with topline results expected to be reported during the week of October 7.
“The completion of our ODYSSEY trial represents a major accomplishment for Clearside and I would like to recognize the Clearside team for the hard work and dedication in conducting the trial and achieving this important milestone,” said CEO George Lasezkay.
“We would also like to extend our sincere appreciation to the participants, clinical sites, and the physician investigators involved in ODYSSEY. At Clearside, we believe there is a compelling market opportunity for CLS-AX to provide patients and physicians with a potentially safer treatment option and reduced treatment burden using axitinib, the highly-potent tyrosine kinase inhibitor (TKI), combined with delivery into the suprachoroidal space using our patented SCS Microinjector®. We look forward to reporting the topline data and also presenting the data at events ahead of the annual meeting of the American Academy of Ophthalmology (AAO) in Chicago.”
CLSD shares regressed 56 cents, or 4.6%, to $11.60.
